Pipeline

MPS II-Strategic Initiative Model

A focused starting point for validating our rare disease discovery thesis.

MPS II (Hunter syndrome)

is a rare X-linked lysosomal disorder caused by deficiency of iduronate-2-sulfatase, resulting in accumulation of glycosaminoglycans (GAGs) and progressive, multisystem disease.

Current therapies do not fully address long-term disease burden and can be complex to deliver, highlighting a critical need for more practical and effective approaches.

At SunForestX Therapeutics, we focus on precision small-molecule strategies to target disease mechanisms at their source—aiming to expand access and improve long-term outcomes for patients.

Epidemiology & unmet need

1:100,000

Male live births

Reported incidence range across geographies

~$1.1 million AUD

Drug-only cost (ERT) per annual

Based on current idursulfase dosage on a 50KG MPS II patient

X‑linked

Inheritance pattern

Primarily affects males, carrier females may show symptoms

Progressive

Disease course

Multisystem accumulation leads to lifelong burden

Development timeline

Discovery & validation

Target identification, mechanism validation, lead optimization

Preclinical development

IND‑enabling studies, formulation, toxicology

Clinical translation

Phase I/II trials, biomarker validation, partnership expansion

Pipeline philosophy

Disease-first prioritisation

Programs are selected around unmet need, translational feasibility, and platform fit.

Mechanism-driven design

Development is grounded in actionable disease biology rather than broad generic screening alone.

Platform expansion

Knowledge gained from MPS II is intended to inform broader rare disease opportunities.

Biotech innovation: AI, multi-omics data, and human-centric approach to rare disease therapy

Bridging computational insight with advanced validation for better patient outcomes.